Variation in Medicaid and commercial coverage of cell and gene therapies

Growth in the availability of cell and gene therapies (CGTs) promises significant innovation in the treatment of serious diseases, but the high cost and one-time administration of CGTs has also raised concern about strain on health plan budgets and inequity in access. We used coverage information fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Beinfeld, Molly T., Rucker, Julia A., Jenkins, Nola B., de Breed, Lucas A., Chambers, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660088/
https://www.ncbi.nlm.nih.gov/pubmed/38023441
http://dx.doi.org/10.1016/j.hpopen.2023.100103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660088/
https://www.ncbi.nlm.nih.gov/pubmed/38023441
http://dx.doi.org/10.1016/j.hpopen.2023.100103

Ejemplares similares